红花素抗脓毒症潜在靶点的筛选与鉴定
该研究用TCMSP分析红花素药代参数(口服生物利用度41.15%、类药性0.24、可旋转键数1),经SwissTargetPrediction与DRAR-CPI筛出115个化合物靶点,从OMIM、CTD、TTD获149个脓毒症疾病靶点,取交集得10个共同靶点。分子对接显示红花素可与这10个靶蛋白结合并作用于关键氨基酸残基。作者据此推测红花素通过调控CTSG、ELANE、LCN2减轻组织器官损伤,调控ADORA1、PTGS2、NOS2、MAPK1并介导PROC、F9抑制凝血以减轻炎症,调控G6PD改善氧化应激,从而防治脓毒症。
要点
- 研究为生物信息学预测,非临床或动物实验,10个靶点均为计算筛选与分子对接结果,尚需实验验证。
- 红花素口服生物利用度41.15%、类药性0.24、可旋转键数1,提示口服吸收好、成药性良好。
- 115个红花素靶点与149个脓毒症疾病靶点取交集,得10个共同靶蛋白:F9、ADORA1、NOS2、MAPK1、CTSG、ELANE、PROC、LCN2、G6PD、PTGS2。
- 分子对接显示红花素能与上述10个靶蛋白结合并作用于关键氨基酸残基,为潜在抗脓毒症靶点。
- 作者推测红花素经CTSG、ELANE、LCN2减轻器官损伤,经ADORA1、PTGS2、NOS2、MAPK1及PROC、F9抑制凝血减轻炎症,经G6PD改善氧化应激。
适用人群与场景
- 原文未提及
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型为生物信息学靶点筛选与分子对接研究,非临床或动物研究,无样本量与中心数。
- TCMSP分析显示红花素口服生物利用度41.15%、类药性0.24、可旋转键数1。
- SwissTargetPrediction与DRAR-CPI共筛出115个红花素潜在靶点;OMIM、CTD、TTD共获149个脓毒症疾病靶点。
- 两网站115个靶蛋白与疾病靶点匹配后得10个共同靶蛋白:F9、ADORA1、NOS2、MAPK1、CTSG、ELANE、PROC、LCN2、G6PD、PTGS2。
- 分子对接分析显示红花素能与上述10个靶蛋白结合并作用于关键氨基酸残基,为潜在抗脓毒症靶点。
证据类型、等级与局限
- 证据类型为生物信息学预测与分子对接研究(综述/计算研究),非RCT、队列或病例对照。
- 局限:结果基于数据库与算法预测,靶点结合与抗脓毒症疗效尚未经体外或体内实验验证,亦无临床数据。
- 原文未报告样本量、中心数或前瞻性验证。
对床旁实践的改变
- 本文为靶点预测研究,尚不能改变急诊/ICU对脓毒症的现有处置;不构成临床用药推荐。
- 适用人群与场景原文未提及;不能据此在脓毒症患者中使用红花素或调整现有治疗。
- 常见陷阱:将分子对接的结合能力误读为临床疗效或决策阈值;将计算筛选靶点当作已验证治疗靶点。
指南或共识出处
- 原文未提及指南或共识;研究数据来源为TCMSP、SwissTargetPrediction、DRAR-CPI、OMIM、CTD、TTD数据库。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To screen and identify the potential targets of carthamin against sepsis by studying the characteristics of carthamin.
METHODS: The pharmacological parameters and molecular characteristics of carthamin were analyzed with the aid of Traditional Chinese Medicine Systems Pharmacology (TCMSP). The targets of carthamin were screened by SwissTargetprediction (a website providing compound target prediction) and Drug Repositioning and Adverse drug Reaction via Chemical-Protein Interactome (DRAR-CPI). The anti-sepsis targets were selected from the three databases of Online Mendelian Inheritance in Man (OMIM), Comparative Toxicogenomics Database (CTD) and Therapeutic Targets Database (TTD). The targets of carthamin screened by the two websites and disease targets selected from the three databases were matched to screen the targets of carthamin against sepsis. The anti-sepsis potential targets of carthamin were identified by molecular docking software.
RESULTS: The oral bioavailability of carthamin was 41.15%, the drug-likeness was 0.24, and the rotational bond number was 1, which indicated that carthamin was well absorbed by oral administration and showed good drug formation. A total of 115 potential targets of carthamin were screened by SwissTargetprediction and DRAR-CPI; 149 disease targets were found from OMIM, CTD and TTD databases; 115 target proteins of carthamin screened by the two websites were matched with the disease targets , and 10 target proteins were found to be both molecular targets and disease targets. The 10 target proteins were coagulation factor IX (F9), adenosine A1 receptor (ADORA1), nitric oxide synthase 2 (NOS2), mitogen activity protein kinase 1 (MAPK1), cathepsin G (CTSG), neutrophil elastase (ELANE), protein C (PROC), lipocalin 2 (LCN2), glucose-6-phosphate dehydrogenase (G6PD) and prostaglandin endoperoxidase 2 (PTGS2). Molecular docking software analysis showed that carthamin had the ability to bind to the above 10 target proteins, which were potential targets of carthamin against sepsis. Carthamin could interact with the key amino acid residues of the targeted proteins, so as to play the corresponding efficacy.
CONCLUSIONS: Carthamin combines with the targets could reduce the tissues and organs damage of sepsis by regulating CTSG, ELANE and LCN2, reduce inflammatory response of sepsis by regulating ADORA1, PTGS2, NOS2, MAPK1 and mediating PROC and F9 to inhibit clotting, and improve oxidative stress, reduce the incidence of sepsis by regulating G6PD, finally, prevented and treated sepsis.
参考来源
- Guo S, Xu Y, Chen G, et al. [Screening and identification of potential targets of carthamin against sepsis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 33565395. doi:10.3760/cma.j.cn121430-20200508-00368
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。